[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-injury":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100651572","phase-4-multicenter-study-to-evaluate-the-safety-and-efficacy-of-symvess-in-a-real-world-setting-in-patients-with-extremity-arterial-injury-requiring-urgent-repair-100651572",false,"NCT07762794","Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent Repair","A Phase 4 Observational Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting for Arterial Replacement or Reconstruction in Patients With Extremity Vascular Trauma","Inclusion Criteria:\n\n1. Aged at least 18 years old\n2. Patient is suitable to be implanted with a Symvess for extremity vascular trauma, in accordance with the approved indication of the USPI\n\n   1. Symvess implant is to be used to re-establish blood flow to one of the major extremity arteries (see Section 4.1 for examples of size appropriate vessels)\n   2. Although the proximal anastomosis may originate in the upper or lower torso region, the distal anastomosis must terminate in the extremity (e.g., below the inguinal crease for lower extremity, in the axillary or more distal in the upper extremity)\n3. Patient or legal representative is able, willing, and competent to give informed consent.\n4. Patient's life expectancy is at least 1 year based on the judgement of the Investigator\n5. Patient must have a home or place of residence whereby he\u002Fshe may be contacted and a support system which would make them suitable for this study of one year follow-up duration\n6. Patient must have confirmed health insurance\n\nExclusion Criteria:\n\n1. Limb at a high risk of amputation due to nature of the initial injury in the judgement of the Investigator, despite adequate revascularization\n2. Patients lacking enough healthy muscle and\u002For soft tissue for adequate coverage of Symvess\n3. Known drug or alcohol abuse that in the opinion of the Investigator would preclude the patient from being suitable for long-term follow-up\n\n   a. Positive screen for illicit drugs (THC use is not exclusionary)\n4. Patient with known coagulopathies or hypercoagulable states (bleeding or clotting disorders)\n5. Known socioeconomic reasons (such as being homeless) that preclude the patient from being suitable for long-term follow-up\n6. Employee of the Sponsor or patient who is an employee or relative of the Investigator","ALL","18 Years",{"count":19,"type":20},125,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this post-marketing observational study is to further assess the long-term safety and efficacy of Symvess in a real-world setting in adult patients with extremity arterial injury.\n\nThe primary objective of the study is to determine Symvess secondary patency at 1 year.\n\nAdditional key secondary objectives, such as limb salvage, infection-free rate, primary patency, and safety, will also be assessed at 1 year.\n\nAll participants will receive Symvess. This is an open-label study and there is no comparator.\n\nParticipants will undergo surgery to repair an extremity arterial injury using Symvess. Participants will be asked to return at regular intervals up to 1 year post-implant to undergo imaging to assess Symvess patency, and for other standard clinical safety and efficacy assessments.",[26,27,28],"Vascular Injury","Arterial Injury","Trauma Injury",[30,31,32,33,34,35],"Trauma","Extremity arterial injury","Symvess","Arterial injury","Vascular injury","Trauma injury","NOT_YET_RECRUITING","2026-08-11",{"date":39,"type":40},"2026-08-13","ACTUAL",{"date":42,"type":20},"2026-09",{"date":44,"type":20},"2030-09",{"name":46,"class":47},"Humacyte, Inc.","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100579503","early-phase-1-therapeutic-strategies-to-reduce-endothelial-ischemia-reperfusion-injury-100579503","NCT06825143","Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury","Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury with Metabolic Syndrome: a Combination Approach with Lactate Administration and Ischemic Preconditioning","Inclusion Criteria:\n\n* Sedentary men and women between the ages of 18-65 years of all races and ethnicity\n* Diet and weight stable for the past 3 months\n* Non-smoking and not using tobacco or electronic cigarettes\n\nExclusion Criteria:\n\n* Use of medications known to affect cardiovascular function\n* Hyperlactemia\n* Type A lactic acidosis\n* Type B lactic acidosis\n* Extracellular hyperhydration or hypervolemia\n* Hyperkaliemia\n* Hypercalcemia\n* Metabolic alkalosis\n* Metabolic acidosis\n* McArdle's Disease\n* Diabetes Type 1 and 2\n* Taking oral contraceptives or hormone replacement therapy\n* Body mass index greater than or equal to 35\n* Smoking or using smokeless tobacco and electronic cigarettes\n* Cardiovascular, cerebrovascular, liver, respiratory, and renal disease\n* Atrial fibrillation or other sustained supraventricular\u002Fventricular arrhythmia\n* Familial hypercholesterolemia\n* Rheumatoid arthritis\n* Sleep apnea\n* Currently pregnant, recent pregnancy, or breast-feeding\n* Autonomic nervous system dysfunction\n* Raynaud's disease\n* Active malignancy excluding basal cell carcinoma of the skin\n* Three or more days of at least 30 minutes of aerobic exercise in the past 3 months\n* Inability to provide consent",true,"65 Years",{"count":58,"type":20},68,[60],"EARLY_PHASE1","The objective of this clinical trial is to better understand how lactate, a naturally occurring energy substance, can be used to lessen damage to the vascular system in adults with a high cardiovascular disease risk.\n\nThe main questions it aims to answer are:\n\n1. Does giving lactate intravenously reduce injury to the vascular system?\n2. Does giving lactate intravenously together with blood flow occlusion - known as ischemic preconditioning, reduce vascular injury better than blood flow occlusion by itself?\n3. How does lactate help the vascular system?\n\nResearchers will compare lactate to a placebo (a look-alike substance that contains no lactate) to see if lactate works to lessen vascular injury.\n\nResearchers will also compare lactate to blood flow occlusion to see which one is better at preventing vascular injury.\n\nResearchers will also compare lactate and blood flow occlusion together to see if combining them works better than either one alone.\n\nIn one visit to the laboratory, participants will:\n\nObtain a measurement of vascular health in an arm Be given liquid lactate, a liquid placebo, and\u002For arm blood flow occlusion Obtain a second measurement of vascular health in an arm.",[63,26,64,65,66],"Metabolic Syndrome","Ischemic Preconditioning","Endothelial Function (reactive Hyperemia)","Endothelial Dysfunction",[68,69,70,71],"endothelial ischemia\u002Freperfusion injury","remote ischemic preconditioning","lactate","metabolic syndrome","2025-02-07",{"date":74,"type":40},"2025-02-13",{"date":76,"type":20},"2026-10-01",{"date":78,"type":20},"2030-06-30",{"name":80,"class":81},"Gary Van Guilder","OTHER",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":82},"100504285","registry-for-vascular-trauma-and-follow-up-examinations-100504285","NCT05846321","Registry for Vascular Trauma and Follow-up Examinations","Inclusion Criteria:\n\n* Age over 18 years\n* Vascular involvement in trauma\n* Isolated vascular injury\n* Written informed consent, except for those deceased from trauma sequelae\n\nExclusion Criteria:\n\n* Minority\n* Lack of consent",{"count":90,"type":20},300,"OBSERVATIONAL","Within the framework of the project presented here, a registry for traumatic vascular injuries will be established at Augsburg University Hospital. Patients who are treated at our hospital for an isolated vascular trauma or a vascular involvement in (poly-)trauma will be included. This is a rare complication of trauma, so data collection in a registry is useful to pool data on therapeutic procedures and outcome.\n\nThese patients differ from the usual vascular surgery patient clientele because there is usually no previous vascular disease. Healthy vessels show different physiological responses than pre-diseased vessels. The usual therapeutic procedures and materials are also developed for arteriosclerotic or aneurysmatic vessels. Therefore, a core objective of this study is to assess long-term outcomes after vascular trauma.",[26],[30,95,96,97,98],"Vascular trauma","Bleeding","Ischemia","Registry","RECRUITING","2023-09-07",{"date":102,"type":40},"2023-09-13",{"date":104,"type":40},"2023-06-01",{"date":106,"type":20},"2030-12-31",{"name":108,"class":81},"University Hospital Augsburg"]